GLUE
NASDAQMonte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc. (GLUE) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for GLUE, including 4 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published Nov 9, 2026.
GLUE rankings
Financial highlights
Full financials- Revenue, TTM
- $70.33M
- Revenue growth
- -61.3%
- Net income, TTM
- -$130.97M
- Net margin
- -186.2%
- Free cash flow, TTM
- -$174.39M
- Cash
- $45.18M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks54+17%
2026-05-172026-11-08
Mix1990d
- Other10(53%)
- SEC Filings4(21%)
- Earnings3(16%)
- Analyst1(5%)
- Insider1(5%)
Activity · 52 weeks10562 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in GoutNEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical data showing that MRT-8102, a NEK7-directed MGD, inhibited NLRP3 inflammaso
- SECSEC Form 10-Q filed by Monte Rosa Therapeutics Inc.10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesPositive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates comparable to placebo; Phase 2 initiation in coronary artery disease anticipated in H1 2027 Initiation of Phase 2 study of MRT-8102 in gout expected in Q4 2026, with data update expected in H2 2027; additional Phase 2 initiation in hidradenitis suppurativa anticipated in H1 2027 Initiated MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients wit
- PRMonte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 33,775 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $10.63 as reported by Nasdaq on November 2, the effective date of the grant or the "Grant Date", which wil
- PRMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ETUBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. GMTJefferies Global Healthcare Conference in London – fireside chat, November 17, 2026, at 10:00 a.m. GMTPiper Sandler 38th Annual Healthcare Conference (New York, NY) – fireside chat, December 1, 20
- PRMonte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study This is the second of multiple studies planned to evaluate MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announce
- INSIDERPrincipal Accounting Officer Bowen Matthew sold $137 worth of shares (13 units at $10.56) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- PRMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $11.26 as reported by Nasdaq on October 1, the effective date of the grant or the "Grant Date", which will
- ANALYSTH.C. Wainwright initiated coverage on Monte Rosa Therapeutics with a new price targetH.C. Wainwright initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $25.00
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD RiskIn obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses HMGB1, calprotectin, S100A12, and SAA, damage-associated molecular patterns (DAMPs) linked to atherosclerotic plaque progression and instability, and IL-1β, all established key pathogenic drivers of
- PRMonte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease RiskBOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic driver
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Nov
- PRMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant or the "Grant Date", which wi
- PRMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ETMorgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026 A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa’s website at ir.monterosatx.com, and arch
- PRMonte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate CancerStudy will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in patients w
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- SECSEC Form 10-Q filed by Monte Rosa Therapeutics Inc.10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesCompleted enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk and cardiometabolic syndrome in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 MODeFIRe-1 Phase 2 study of MRT-2359 activated, in combination with apalutamide in metastatic castration-resistant prostate cancer patients (mCRPC) with androgen receptor (AR) mutations Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 (DDY391) act
- INSIDERPresident & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
GLUE FAQ
10 questionsWhat is the latest news on GLUE?
In the last 30 days Quantisnow tracked 7 wire items for GLUE: 4 press releases and news items, 2 SEC filings and 1 earnings update. The most recent was published on November 9, 2026.What is GLUE revenue?
Monte Rosa Therapeutics Inc. (GLUE) reported $70.33M of revenue for the twelve months ended Sep 30, 2026. That is down 61.3% from the year before. Revenue for fiscal 2025 was $123.67M.Is GLUE profitable?
No. Monte Rosa Therapeutics Inc. reported a net loss of $130.97M for the twelve months ended Sep 30, 2026.How much cash and debt does GLUE have?
Monte Rosa Therapeutics Inc. reported $45.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does GLUE stock trade?
Monte Rosa Therapeutics Inc. (GLUE) is listed on NASDAQ.What sector and industry is GLUE in?
Monte Rosa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Monte Rosa Therapeutics Inc. go public?
Monte Rosa Therapeutics Inc. (GLUE) completed its IPO in 2021.What are analysts saying about GLUE?
Across the last 8 analyst actions on Monte Rosa Therapeutics Inc., there were 1 upgrade and 1 downgrade. The most recent action was from H.C. Wainwright: Buy with a $25.00 price target on 2026-10-01. Recent price targets range from $11.00 to $25.00.What companies are similar to GLUE?
Notable peers in the same industry include AMGN (Amgen Inc.), EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare GLUE side-by-side with any of them on Quantisnow.How can I track GLUE on Quantisnow?
Quantisnow aggregates Monte Rosa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLUE to receive live email and push alerts on every new disclosure.